Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
August 27th, 2026
Matthew Pearson Quoted on AI, Chatbots, and California Privacy Litigation
Matt Pearson is quoted in the MLex article, AI Changes the Conversation Around California’s Wiretap Law, which examines how courts are applying California's wiretapping statutes to artificial intelligence technologies, including AI notetakers and chatbots. Pearson discusses the challenges plaintiffs face in bringing claims under the California Invasion of Privacy Act, explaining that courts will closely scrutinize when and how information is transmitted and whether communications are intercepted while in transit. He also highlights evolving judicial interpretations of what constitutes a confidential communication in the context of AI-driven services. Read the full MLex Article. (Behind paywall)
Other Quoted
Climate Diaries Cannes Lions 2026
Jeffrey A. Greenbaum is featured in the 51toCarbonZero article, Climate Diaries Cannes Lions 2026, which features eleven interviews with senior leaders from across the media and advertising industry conducted at the Cannes Lions International Festival of Creativity. Read more.
August 5 2026
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
